Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioShield II Patent Extensions Will Increase Drug Costs, GPhA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The Generic Pharmaceuticals Association supports the overall goals of the bill but claims product exclusivity extensions will needlessly inflate pharmaceutical costs. The association will testify before the Oct. 6 joint Senate Judiciary/Health Committee hearing.

You may also be interested in...



GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives

The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.

GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives

The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.

"BioShield II" Hearing Reveals Continued Division On IP Incentives

GPhA should provide more input on its concerns over intellectual property protections in the bill, Sen. Enzi says. Though R&D incentives are needed, a "wild card" exclusivity provision could allow unfair patent extensions, Sen. Schumer argues.

Topics

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel